Insmed Incorporated (INSM) Rallies After FDA Approves Brinsupri, Shares Jump 9%

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Insmed Incorporated is one of them.

Insmed Incorporated (NASDAQ:INSM) tops our list for being one of the best performing stocks. It is a biopharmaceutical company focused on rare diseases, with a portfolio targeting serious conditions with unmet medical needs. Its flagship product, ARIKAYCE® (amikacin liposome inhalation suspension), addresses lung infections and has shown strong market growth.

Recently, INSM gained significant investor attention after FDA approval of Brinsupri for non-CF bronchiectasis. This milestone boosted stock performance, with shares rising nearly 9%, and prompted analysts to raise price targets, JPMorgan to $135, Stifel to $145, and H.C. Wainwright to $240, reflecting Brinsupri’s potential to generate $7 billion in revenue by 2033.

Financially, the business reported Q2 2025 revenues of $107.4 million for ARIKAYCE, up 19% year-over-year, with a strong gross margin of 75.7%, despite a net loss of $321.7 million. The company also completed a public offering, raising approximately $823 million to fund pipeline development and commercialization.

Looking ahead, Insmed Incorporated (NASDAQ:INSM)’s pipeline includes several promising late-stage assets. Brensocatib received FDA approval on August 12, 2025, while the Treprostinil Palmitil Inhalation Powder (TPIP) program is progressing toward Phase 3 studies for pulmonary hypertension, expected to begin in late 2025 and early 2026. These developments position INSM for continued growth and expansion in the rare disease market.

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.